BioMarin Pharmaceutical: Oppenheimer cuts target price to $94 from $97
BMRN•Oppenheimer cut its target price for BioMarin Pharmaceutical to $94 from $97.
Related News
Capricor Therapeutics schedules third-quarter financial results release
CAPR•
Fortune Brands Innovations names Morgan Fox chief legal officer, corporate secretary
FBIN•
US small business job growth holds steady in October, Paychex says
PAYX•
NexPoint Residential Trust declares quarterly dividend of $0.53 per share
NXRT•
Interface completes social life cycle assessment of natural rubber
TILE•